Horizon Pharma Bolsters Orphan Drug Portfolio with US$800 M Purchase of Raptor Pharmaceuticals
By Jawala Prasad
Pharma Deals Review: Vol 2016 Issue 9 (Table of Contents)
Published: 21 Sep-2016
DOI: 10.3833/pdr.v2016.i9.2192 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Signalling its intention to focus on the orphan drug space, Horizon Pharma has signed a deal worth approximately US$800 M to acquire rare disease specialist Raptor Pharmaceuticals...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS